Werum and Systec & Solutions Present Joint Approach for Production Enhancement

At the 2015 PAS-X User Group Meeting in Parsippany, New Jersey, companies Werum IT Solutions and Systec & Solutions presented a new, jointly developed approach for enhanced usability in controlling pharmaceutical and biopharmaceutical production processes on the shop floor.

Werum IT Solutions is a provider of manufacturing IT solutions and manufacturing execution systems for the pharmaceutical industry, and Systec & Solutions is a specialized manufacturer of good manufacturing practice IT hardware solutions for the pharmaceutical industry.

Durata Therapeutics Relocates Headquarters to Chicago

The biotech drug development company is moving its offices from New Jersey to downtown Chicago.

Biotech drug development company Durata Therapeutics is moving its global headquarters to Illinois from New Jersey, Governor Pat Quinn said Wednesday.

The company is relocating to 200 S. Wacker in Chicago from New Jersey. Quinn's office said the company expects to create 100 new jobs here in the next three years.

Durata wil get tax credits, based on job creation, that can be used against corporate income taxes, to be paid over 10 years under the Economic Opportunity for a Growing Economy (EDGE) program.

No votes yet

Fujifilm Diosynth Biotechnologies Manufactures New Licensed Biopharmaceutical

Jetrea is FDA-approved for treatment of symptomatic vitreomacular adhesion.

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA). 

No votes yet

Biopharma M&A Trends Held Steady in 2011

Research indicates the number of mergers and acquisitions increased in 2011, though the number fell short of industry expectations.

Given the narrow initial public offering window, declining venture investments and tough capital markets, mergers and acquisitions (M&A) have become the exit of choice for many biopharmaceutical companies. In 2011, there were more M&As than in 2010, deal value was higher, but it still wasn't the flood of deals many industry observers had expected, according to BioWorld.

No votes yet

PhRMA Announces Board Appointments

At the annual meeting of Pharmaceutical Research and Manufacturers of America (PhRMA), Christopher Viehbacher, chief executive officer of sanofi-aventis, resumed his role as board chairman, while John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Co. was elected as chairman-elect of the PhRMA Board of Directors and Robert J. Hugin, president and chief executive officer of Celgene Corp. was elected PhRMA’s board treasurer. Viehbacher assumed the chairmanship in December 2010.

West Plastic Syringe With Prefixed Needle Targets Biologics

West ( has expanded its family of cyclic olefin polymer (COP) products with the introduction of the Daikyo Crystal Zenith (CZ) 1-mL long insert needle syringe system. The 1-mL long format has been favored for packaging of biologics in prefilled syringes. In manufacturing at West’s Scottsdale, AZ, facility, the needle is insert-molded into the plastic syringe.

dhesives and tungsten residues—potential contaminates in glass syringes with staked needles—are avoided, says Graham Reynolds, vice president, marketing and innovation, West.

No votes yet

Comfort In Parenteral Delivery

Automated device functions and safety features make parenteral administration less onerous for self-treating patients.


By David Vaczek, Senior Editor

Advanced parenteral delivery solutions are affording product differentiation and therapeutic benefits across a range of therapies.

In needle-based injection, cartridge-based pens and prefilled syringes loaded into disposable auto injector devices offer features that support easier self administration by patients.

Your rating: None Average: 5 (3 votes)

Tech Corner: Handled with Care

A machinery manufacturer took time to understand a cytotoxic drug filling line in order to deliver a solution offering heightened control and safety.

Last year, Baxter’s BioPharma Solutions business ( expanded its cytotoxic contract manufacturing capacity to increase support of early-phase oncology sterile drug formulation through commercial scale-up, introduction, and lifecycle management. In need of a capacity extension, Baxter replaced a vial-filling machine with a highly automated filling line including a closed Restricted Access Barrier System (cRABS) dedicated for aseptic manufacturing of cytotoxics at its manufacturing facility in Halle (Westfalen), Germany.

No votes yet

Illinois Governor Opens 2010 BIO International Convention, Meets Vetter

Illinois Governor Pat Quinn cut the ribbon at the 2010 BIO International Convention and met with industry leaders, including executives from Vetter, a provider of aseptic prefilled drug-delivery systems.

Biomedical Jobs Critical to California Economy

The biomedical industry is a critical factor in California’s efforts to achieve economic recovery, according to a report by the California Healthcare Institute (CHI) and PricewaterhouseCoopers LLP.

Syndicate content